May 2025 Product News

Rx Product

Dexcom G7 15 Day

From: DexCom, Inc

The FDA cleared the Dexcom G7 15 Day continuous glucose monitoring (CGM) system for individuals older than 18 years with diabetes, making it the longest-lasting CGM system for patients, excluding implantable CGMs. The system furthers the performance of the Dexcom CGM, which has been clinically proven to lower hemoglobin A1c levels, reduce hyper- and hypoglycemia, and increase time in range for patients. In addition to these features, the Dexcom G7 15 Day system has 15.5 days of wear, best-in-class accuracy with an overall mean absolute relative difference of 8%, and easier glucose management with fewer monthly sensors and reduced waste.

For more information: Dexcom.com

Efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)

From: argenx SE

The FDA granted regulatory approval to efgartigimod alfa and hyaluronidase-qvfc (Vyvgart Hytrulo) prefilled syringe for selfinjection for the treatment of adults with generalized myasthenia gravis who are anti–acetylcholine receptor antibody positive and those with chronic inflammatory demyelinating polyneuropathy. The prefilled syringe was approved for use as a 20- to 30-second subcutaneous injection, administered by a health care professional, a caregiver, or the patient themselves. Patients can self-inject the treatment following proper counseling in the subcutaneous injection technique, offering a new opportunity for pharmacists to counsel patients.

For more information: vyvgarthcp.com

OTC Product

PBZ OTC Pyribenzamine Antihistamine Cream

From: Kingsway Pharmaceuticals

PBZ OTC Pyribenzamine Antihistamine Cream has been released as an OTC product, offering greater access to the only topical itch relief cream for individuals 2 years and older. The cream can be used for bug bites, rashes, sunburns, and more, helping relieve itching fast. The key ingredient, an oral antihistamine, was historically a prescription product. Now, however, the product is available OTC to deliver targeted itch relief in a single application.

For more information: pbzotc.com

Generic Product

Dasatinib

From: Zydus Lifesciences Limited

Compare to: Sprycel

The FDA granted final approval to dasatinib tablets, the generic drug for Sprycel, for the treatment of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase among newly diagnosed individuals. Dasatinib is also used to treat individuals with Ph+ CML with resistance or intolerance to prior therapies. The generic tablet is available in 20-, 50-, 70-, 80-,100-,and 140-mg doses.

For more information: zyduslife.com